Humacyte director buys 10,000 shares at $0.693

Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share.

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share. Following this transaction, he directly owns 40,000 shares of Humacyte common stock.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Jones Keith Anthony

Role Director

Bought 10,000 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$0.693	$7K

Holdings After Transaction: Common Stock — 40,000 shares (Direct)

Key Figures

Shares purchased: 10,000 shares of Common Stock Purchase price per share: $0.693 per share Shares owned after transaction: 40,000 shares of Common Stock

3 metrics

Shares purchased 10,000 shares of Common Stock Purchase reported on August 20, 2026

Purchase price per share $0.693 per share Price for the 10,000-share purchase on August 20, 2026

Shares owned after transaction 40,000 shares of Common Stock Direct ownership following the reported purchase

Key Terms

Form 4, Common Stock, open market or private transaction

3 terms

Form 4 regulatory

"reported purchasing 10,000 shares of Humacyte common stock on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"10,000 shares of Humacyte common stock in an open market"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"purchase in an open market or private transaction on August 20, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Humacyte (HUMA) report for Keith Anthony Jones?

Humacyte director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock on August 20, 2026 in an open market or private transaction at $0.693 per share.

How many Humacyte (HUMA) shares does Keith Anthony Jones own after this Form 4 transaction?

After the reported transaction, Keith Anthony Jones directly owns 40,000 shares of Humacyte common stock, as stated in the Form 4 following his 10,000-share purchase on August 20, 2026.

Was the Humacyte (HUMA) insider trade a purchase or a sale?

The reported Humacyte insider trade was a purchase. Director Keith Anthony Jones acquired 10,000 shares of Humacyte common stock at $0.693 per share in an open market or private transaction.

At what price did Keith Anthony Jones buy Humacyte (HUMA) stock?

Keith Anthony Jones bought Humacyte common stock at a price of $0.693 per share for 10,000 shares on August 20, 2026, according to the Form 4 filing.

Is the reported Humacyte (HUMA) insider ownership direct or indirect?

The Form 4 states that Keith Anthony Jones’ ownership of Humacyte common stock after the transaction, totaling 40,000 shares, is held as direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Keith Anthony

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2026		P		10,000	A	$0.693	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Keith A. Jones by Dale A. Sander as Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)